Egalet signs agreement with Septodont
Under this agreement Septodont will promote SPRIX (ketorolac tromethamine) Nasal Spray exclusively to dentists in the United States using its focused specialty sales force. Under the terms of
QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.
Mirvetuximab soravtansine is currently being evaluated in the phase Ib/II FORWARD II study in combination with anticancer agents including Doxil (doxorubicin), Avastin (bevacizumab) and Paraplatin (carboplatin). The mirvetuximab